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Liver immunology and its role in inflammation and
homeostasis
Mark W Robinson1, Cathal Harmon1 and Cliona O’Farrelly1,2
The human liver is usually perceived as a non-immunological organ engaged primarily in metabolic, nutrient storage
and detoxification activities. However, we now know that the healthy liver is also a site of complex immunological
activity mediated by a diverse immune cell repertoire as well as non-hematopoietic cell populations. In the non-
diseased liver, metabolic and tissue remodeling functions require elements of inflammation. This inflammation, in
combination with regular exposure to dietary and microbial products, creates the potential for excessive immune
activation. In this complex microenvironment, the hepatic immune system tolerates harmless molecules while at the
same time remaining alert to possible infectious agents, malignant cells or tissue damage. Upon appropriate
immune activation to challenge by pathogens or tissue damage, mechanisms to resolve inflammation are essential
to maintain liver homeostasis. Failure to clear ‘dangerous’ stimuli or regulate appropriately activated immune
mechanisms leads to pathological inflammation and disrupted tissue homeostasis characterized by the progressive
development of fibrosis, cirrhosis and eventual liver failure. Hepatic inflammatory mechanisms therefore have a
spectrum of roles in the healthy adult liver; they are essential to maintain tissue and organ homeostasis and, when
dysregulated, are key drivers of the liver pathology associated with chronic infection, autoimmunity and malignancy.
In this review, we explore the changing perception of inflammation and inflammatory mediators in normal liver
homeostasis and propose targeting of liver-specific immune regulation pathways as a therapeutic approach to
treat liver disease.
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INFLAMMATORY PROCESSES AND LIVER
HOMEOSTASIS
The human liver is classically perceived as a non-immunological
organ, required for metabolic activities, nutrient storage and
detoxification. We now know that the liver is also an
immunologically complex organ, responsible for the production
of acute phase proteins, complement components, cytokines
and chemokines, and contains large, diverse populations of
resident immune cells.1–3 In healthy individuals, the liver is
constantly bombarded by a stream of dietary and commensal
bacterial products with inflammatory potential. These gut-
derived molecules must be tolerated by the hepatic immune
system, which, at the same time, is poised to respond to danger.
In the healthy liver, constantly changing metabolic and tissue
remodeling activity, combined with regular exposure to micro-
bial products, results in persistent, regulated inflammation.
These inflammatory processes act in a tightly controlled fashion
and are stimulated to additional activity only when the liver is
required to rid itself of hepatotropic pathogens, malignant cells
or toxic products of metabolic activity. Failure to clear such
dangerous stimuli and resolve inflammation, leads to chronic
infection, autoimmunity or tumor growth. This is inevitably
associated with chronic pathological inflammation and dis-
rupted tissue homeostasis, which can progress to fibrosis,
cirrhosis and liver failure.
Inflammation is essential to combat infection; however,
inflammatory mechanisms also underpin normal physiological
events in the healthy body, including embryonic implantation,4
fetal development,5 involution post-partum and tissue repair.6
In the liver, homeostatic inflammatory processes control
hemodynamic changes, capillary permeability, leukocyte migra-
tion into tissues and secretion of inflammatory mediators. This
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homeostatic inflammation is tightly regulated and the activa-
tion of inflammatory processes is intimately linked to mechan-
isms that resolve inflammation and promote tissue
regeneration (Figure 1). This controlled inflammation is
essential to maintain tissue and organ homeostasis and yet,
when dysregulated, drives pathology and organ damage
(Figure 1). In this review, we demonstrate an emerging role
for inflammation and inflammatory mediators in normal liver
homeostasis, in regulating the liver immune system and in liver
regeneration following various forms of liver damage. We
propose that homeostatic inflammation should be viewed as a
normal part of the healthy liver and that therapeutic strategies
targeting liver disease be designed to restore these homeostatic
inflammatory processes.
THE IMMUNOLOGICAL STRUCTURE OF THE LIVER
The liver functions as an important buffer between gut
contents and systemic circulation – 80% of the hepatic blood
supply is delivered from the gut via the portal vein. This low
pressure blood supply is rich with harmless dietary and
environmental antigens as well as molecules from the micro-
flora of the gut. The liver must tolerate this immunogenic load
while still providing immunosurveillance for pathogenic infec-
tions and malignant cells. Upon entering the liver venous blood
from the gut mixes with oxygen-rich blood from the hepatic
artery and drains through the hepatic sinusoids to the central
veins through plates of hepatocytes. The sinusoids are lined by
specialized liver sinusoidal endothelial cells (LSEC) that contain
numerous fenestrations, allowing blood to pass through the
LSEC layer to the underlying hepatocytes.
This organization allows for the rapid exchange of molecules
from blood into hepatocytes and facilitates the removal and
degradation of immunogenic molecules (for example, bacterial
endotoxin) in the liver (Figure 2). Pattern recognition receptors
(PRR) expressed by hepatocytes and liver-resident macrophages
(known as Kupffer cells (KC)), bind to microbial associated
molecular patterns (MAMP)7,8 and damage-associated molecular
patterns (DAMP),9 which are present in high quantities in the
blood arriving from the portal vein. Upon binding, these MAMPs
and DAMPs are phagocytosed and subsequently degraded by
hepatocytes and KCs, without the production of inflammatory
mediators that usually accompany PRR signaling. This detox-
ification of blood from the gut protects the rest of the body from
excessive immune activation and influences the unique immu-
nological environment within the liver.
The low pressure blood flow, fenestrated endothelium and
lack of a basement membrane10 also facilitates intimate
interactions between resident immune cells and non-
hematopoietic hepatic cells. These resident immune cell
populate the liver sinusoids and the sub-endothelial compart-
ment, the space of Disse, where lymph collects and flows into
lymphatic vessels running along the portal tract. These resident
immune cells include professional antigen presenting cell
(APC) populations, myeloid cells, as well as innate and adaptive
lymphoid cell populations.11–13 While several liver-resident
immune cell populations are well recognized (for example,
KCs), the full spectrum of immune cells resident within the
liver is still unclear. This is particularly true in humans, and
further studies are required to define phenotypically distinct
liver-resident immune cell populations. In the context of the
healthy adult liver, these liver-resident populations play vital
roles in regulating inflammation and maintaining organ home-
ostasis and the immunological roles of individual liver-resident
immune cell populations are described in further detail in this
issue of Cellular and Molecular Immunology.
Figure 1 The role of inflammatory processes in liver homeostasis
and pathology. Inflammatory processes in the liver are involved in
both homeostasis (organ and systemic) and pathology. Homeostatic
inflammation is tightly regulated by mechanisms that act to resolve
inflammation in order to avoid the pathological consequences of
excessive inflammation.
Figure 2 Immunological and metabolic roles of hepatocytes.
Hepatocytes perform a number of important immunological roles,
in addition to their essential metabolic roles. These include: the
production of plasma proteins such as clotting factors, complement
and antimicrobial proteins; the production of acute phase proteins
upon local or systemic infection; and antigen presentation to T cells
within the liver.
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Liver Myeloid Immune Cell Populations
Macrophages are key detectors of microbial molecules and
producers of inflammatory mediators in the body. KCs account
for up to 90% of the total population of fixed macrophages in the
body and constitute almost a third of the non-parenchymal cells
in the liver.14 KCs are equipped with a massive array of PPRs,15
complement receptors16 and Fc receptors,17 through which they
respond with increased phagocytic activity and production of
inflammatory cytokines. They have essential roles in immune
regulation, tissue repair and liver regeneration18 and are capable
of responding to cytokine, Toll-like receptor (TLR),19 RIG-like
receptor and NOD-like receptor signaling.20
Dendritic cell (DC) populations, including both myeloid
DCs and plasmacytoid DCs, are found in the healthy liver.
Hepatic DC populations are described as phenotypically
immature although they can stimulate strong T-cell responses
in certain situations.21 Recently a sub-population of human
hepatic CD141+ DCs have been shown to be potent cytokine
producers and activators of T cells.11
Myeloid-derived suppressor cells (MDSC) are also present in
the healthy liver22 and are expanded during chronic liver
disease.23 MDSCs are defined by their ability to suppress T-cell
activation through the production of the immunosuppressive
molecules IL-10, transforming growth factor (TGF)β and
arginase.24 Granulocytic cells, such as neutrophils, are thought
to be largely absent in the healthy liver, only accumulating in
response to infection and inflammation.25 However, neutro-
phils and their progenitors share several phenotypic markers
with MDSCs and comprehensive data characterizing these
populations in the human liver are lacking.
Liver Lymphoid Immune Cell Populations
The diverse range of innate lymphocytes in the adult liver includes
natural killer (NK) cells, NK T cells (NKT) (including populations
of CD1d-restricted invariant NKT cells), mucosal associated
invariant T cells and γδ T cells.12,26–28 Hepatic innate lymphocyte
populations are potent cytokine producers and influence both
innate and adaptive immune responses in the liver. The repertoire
of liver innate lymphocytes is strikingly different between mice
and humans. In mice, NKT cells and NK cells make up to 40%
and 10% of total liver lymphocytes respectively, while in humans,
these percentages are reversed, with NK cells predominating.29 In
humans, CD56bright NK cells are particularly enriched in the liver
where they constitute over 50% of the total hepatic NK
population, compared with 10–15% in peripheral blood.30,31 In
mice, invariant NKT cells preferentially home to the liver where
they adhere via LFA/ICAM binding, and form a highly tissue-
resident immune cell population.32
Populations of adaptive lymphocytes, including classic major
histocompatibility complex (MHC)-restricted CD4+ and CD8+
T cells as well as B cells, are found in healthy liver. The liver is
particularly enriched in CD8+ T cells, activated T cells and
memory T cells.13,33 Accumulation of these T-cell subsets in
the liver is associated with T-cell apoptosis and deletion leading
to the liver having been described as a ‘graveyard’ for T
cells.34,35 Populations of B cells are also present in the human
liver, where they account for up to 8% of the total lymphocyte
population.13 Specific hepatic B cell subpopulations, such as the
innate-like CD5+ B cell population, are further expanded in
the liver during hepatotropic viral infection.36,37
Hematopoietic Progenitor Cell Populations in the Liver
While hematopoietic cell development is classically assumed to
be limited to the bone marrow in healthy adults, it has
been hypothesized that some hepatic immune populations
differentiate locally.38,39 The ability of the liver to act as a site of
hematopoiesis when under stress is well described and
hematopoietic stem cells are thought to contribute to mixed
chimerism following liver transplant in murine models.40
Moreover, purified liver hematopoietic progenitor cells have
been shown to reconstitute immune cell populations following
lethal irradiation in mice.41 The adult human liver also
contains populations of progenitor cells, which express surface
markers characteristic of immature hematopoietic cells and
form multi-lineage hematopoietic colonies upon in vitro
culture.38,39 These hepatic myeloid and lymphoid progenitor
populations may contribute to the development of phenotypi-
cally distinct liver-resident immune cell populations through
local hepatic immune cell differentiation.
Immune-Regulating Liver Non-Hematopoietic Cell
Populations
In addition to hepatic immune cell populations, non-
hematopoietic cells in the liver play key roles in local
and systemic innate immunity and inflammation. LSECs,
hepatocytes and hepatic stellate cells (HSC) all express a range
of PRRs.19,42,43 Expression of TLRs, carbohydrate receptors and
scavenger receptors by non-immune cells in the liver comple-
ments KC detection and clearance of MAMPs from the portal
blood supply and regulates the production of inflammatory
mediators from non-immune cells within the liver.
LSECs, and hepatocytes express variable levels of Class II MHC
molecules and are capable of presenting antigens to classical T
cells.1,21 Under inflammatory conditions LSEC-primed T cells
can develop into functional T effector cell populations, in the
absence of CD4+ T-cell activation, and contribute to pathogen
immunity.44 Murine hepatocytes also express the MHC-like
molecule CD1d, enabling lipid presentation to invariant NKT.45
In contrast, it has been difficult to demonstrate CD1d expression
by healthy human hepatocytes, although it is increased in the
context of hepatitis C virus infection.46
THE LIVER MICROENVIRONMENT AND IMMUNE
REGULATION
The anatomical structure, resident immune cell repertoire and
state of constant stimulation in the liver combine to create a
unique cytokine/growth factor milieu. This microenvironment
determines the balance between tolerance and inflammation in
the healthy liver. The hepatic blood supply is a significant
contributor to the unique liver microenvironment. Cells within
the liver are subject to persistent signaling from dietary and
commensal molecules, which induces a state of tolerance as
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discussed in more detail below. The healthy adult liver has an
active and complex cytokine milieu, which includes basal
expression of pro-inflammatory (IL-2, IL-7, IL-12, IL-15 and
interferon (IFN)γ) and anti-inflammatory (IL-10, IL-13 and
TGFβ) cytokines.47,48 This cytokine milieu exists in the absence
of infection or pathological inflammation, and presumably
arises through normal physiological processes within the
healthy liver. These processes likely include PRR signaling
induced by gut-derived molecules in both non-hematopoietic
and myeloid cell populations, as well as cytokine production by
activated hepatic lymphoid immune cell populations.49
The hepatic microenvironment is further influenced by the
high levels of dietary fats and carbohydrates in the hepatic
blood supply. Carbohydrates are taken up by hepatocytes and
stored as glycogen, while dietary fats, transported from the gut
as chylomicrons, are processed into a range of lipoproteins
that in turn distribute cholesterol and triglycerides throughout
the body (Figure 2). Importantly these metabolic processes are
intimately linked to liver inflammation through the inflamma-
tory effects of metabolites such as succinate50 as well as
triglyceride and cholesterol levels, which promote TLR signal-
ing and inflammasome activation.51 The metabolic regulation
of inflammation is important in non-alcoholic fatty liver
disease where elevated pro-inflammatory cytokines, which
contribute to liver fibrosis, are observed.52 In mouse models,
this pro-inflammatory profile can be replicated by a high-fat
diet, driven in part by the sensitization of hepatocytes to TLR
agonists by saturated fatty acids.53 Metabolic regulation of liver
hepatocytes is also evident in hepatitis B virus and hepatitis C
virus infections, where metabolic changes in infected hepato-
cytes promote viral replication.54,55 It is likely that these
metabolic changes also influence the inflammatory immune
response to viral infection.
Indeed, these metabolic links with inflammation extend
beyond hepatocytes and also influence macrophage and DC
functions. Both macrophages and DCs undergo metabolic
reprogramming upon activation, switching from oxidative
phosphorylation to aerobic glycolysis, termed the Warburg
effect.56 This switch is essential for the production of pro-
inflammatory mediators in macrophages however the influence
of metabolism on liver KC function is presently unknown. At
normoxia, the switch to aerobic glycolysis in macrophages
results in increased succinate levels that in turn activate HIF1α
and IL1β production.50 HIF1α is also activated by hypoxia yet
despite the liver being in a constant state of low oxygen tension
(due to blood from the portal vein), a hypoxia response is not
induced in healthy hepatic cells.57 This suggests that cells
within the liver may have a unique response to metabolic
signals that are known to drive inflammation and these
unique metabolic signals likely contribute to the regulation of
liver-immigrating immune cell populations. A deeper under-
standing of the role of the dynamic liver microenvironment in
organ homeostasis is required to provide a context to the
changes that occur during human liver pathology.
INFLAMMATORY PROCESSES IN THE HEALTHY LIVER
Inflammation and inflammatory mediators, generated by liver-
resident immune cell populations and non-hematopoietic cells,
play essential roles in maintaining local liver and systemic
homeostasis. These homeostatic roles must be recognized when
considering the role of inflammation and liver-resident immune
cell populations in liver disease and pathology. Liver inflamma-
tion should be considered as a highly dynamic and complex
network of responses, which collectively aim to maintain organ
and also systemic homeostasis in healthy individuals.
The Tolerogenic Liver
The healthy liver is often described as being immunologically
tolerogenic58,59 nevertheless it is evident that rapid and robust
liver immune responses are successfully generated in many
circumstances. The concept that the liver is an immunologi-
cally tolerant organ arose in the transplantation field when it
was first observed in pigs that allogeneic liver transplantation
was significantly better tolerated than other allogeneic organ
transplantation, which induced rapid rejection.60 This concept
is supported by the low levels of immunosuppression generally
required by liver transplant recipients. Indeed, in certain
individuals, immunosuppression can be completely stopped
following liver transplantation without subsequent graft
rejection.61 Furthermore, the ability of hepatic tolerance to
induce systemic tolerance to co-transplanted organs highlights
the powerful tolerogenic properties of the liver.62
Resident myeloid cells contribute to the maintenance of
hepatic tolerance. KCs respond to bacterial endotoxin
by producing anti-inflammatory cytokines such as IL-10 and
prostaglandins.63,64 These downregulate expression of
co-stimulatory molecules on APCs, preventing activation of
CD4+ T cells and limiting the adaptive immune response.65,66
Presentation of particulate antigens by KCs preferentially
expands IL-10 producing T regulatory cell populations indu-
cing antigen-specific tolerance.67 Similarly, hepatic myeloid
DCs are less potent activators of T cells and produce
significantly more IL-10 compared with spleen derived myeloid
DCs.68–70 Hepatic plasmacytoid DCs also appear phenotypi-
cally immature and are not effective T-cell activators ex vivo;
however, activation via growth factors or TLR agonists induces
maturation and effective antigen presentation.71 Hepatic plas-
macytoid DCs have also been shown to be capable of IL-10
production and activation of regulatory T cells.72 In addition to
these professional APC populations in the liver, LSECs and
hepatocytes possess the ability to directly present antigen to T
cells.1,21 Under certain conditions HSCs may also directly
present antigen to T cells as well as influence antigen
presentation as a bystander cell.73 The presentation of antigens
in the liver biases T cells towards tolerance due to a lack of
co-stimulatory molecules and CD4+ T-cell help, required for
efficient T-cell differentiation.74,75
The tolerogenic liver environment is further maintained by
regulatory myeloid populations such as MDSCs. MDSCs
mediate their suppressive activity through the production of
the immunosuppressive cytokines IL-10 and TGFβ, and the
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production of arginase and IDO, which limit essential amino
acids required for immune cell activation and proliferation.24
Transmigration of monocytes through LSECs leads to MDSC
differentiation76 and MDSCs are activated during the liver
acute phase response77 contributing to the immunoregulatory
potential of the liver.
Systemic Homeostasis and the Acute Phase Response
A key systemic function of the liver is serum protein production.
The liver normally synthesizes the majority of serum proteins,
including complement proteins, albumin, fibrinogen, clotting
factors, transport proteins, protease inhibitors and lipoproteins
(Figure 3). These proteins are involved in the systemic transport
of nutrients, in the regulation of blood osmotic pressure and act
as inactive precursors of several innate immune mediators. The
liver also has a central role in detecting and responding to
inflammatory signals from other sites in the body (Figure 3).
During the early stages of extra-hepatic inflammation, cytokines
produced by immune cells enter the blood stream and are
detected by liver hepatocytes, which initiate the systemic acute
phase response (APR).78 Hepatocytes increase acute phase
protein production by orders of magnitude and also synthesize
IL-6, which acts to amplify the APR.
The acute phase proteins produced by hepatocytes have direct
effector function (Table 1) and are responsible for the systemic
effects of inflammation, which promote pathogen clearance.78–80
The acute phase proteins drive a range of mechanisms through-
out the body including leukocytosis in the bone marrow,
changes in the brain that mediate pyrexia and alter behavior,
and massive immune cell infiltration to the site of initial
inflammation. At the same time the APR includes a range of
processes to limit excessive inflammation. These processes
include the inhibition of neutrophil function by protease
inhibitors, such as α2-macroglobulin, the inhibition of TNF
production from KC by C-reactive protein,81 and the recruit-
ment of suppressive MDSC populations by serum amyloid A.77
These processes act to limit bystander tissue damage caused by
the inflammatory process and enhance the repair process.
Liver Immunity and Resolving Fibrosis
While maintaining an overall tolerogenic environment, the
hepatic immune system must be capable of rapid, controlled
responses to tumor cells and pathogenic microorganisms.
Many pathogens, including several species of viruses, bacteria
and parasites, specifically target the liver.58 Effective local
immunity is essential for detecting and clearing these hepato-
tropic pathogens. During acute liver insult activated KCs can
become potent producers of pro-inflammatory cytokines such
as IL-1, IL-6 and TNF-α as well chemokines such as MIP-1α
and RANTES.82,83 This KC pro-inflammatory response is
induced following signaling via MyD88-independent TLRs
(for example, TLR3), but not MyD88-dependent pathways,
which instead induce IL-10 production.84 Potent pro-
inflammatory CD141+ myeloid DCs have also been demon-
strated in healthy adult liver, capable of inducing IFN-γ
and IL-17 production from T cells.11 In this inflammatory
microenvironment, liver-primed T cells can develop into
functional T effector cell populations and mediate pathogen
clearance, even in the absence of classical CD4+ T cell help.44
Acute liver inflammation leads to the recruitment and
activation of leukocyte populations, and the induction of
fibrotic responses at the site of inflammation,85 as summarized
in Figure 4. The resolving fibrosis observed during acute injury
acts to protect surviving hepatocytes by reducing pro-apoptotic
signaling and increasing resistance to a range of toxins.86 This
fibrotic process is regulated by inflammatory cytokines and
growth factors, released by leukocytes that traffic to the
damaged tissue. These cytokines include TNFα, IL-6, platelet-
derived growth factor and TGFβ. These cytokines lead to
activation and proliferation of HSCs, which are potent produ-
cers of extra-cellular matrix components, including
α-smooth muscle actin and type I collagen.87 Liver fibrosis is
Figure 3 Regulation of systemic homeostasis by the liver. In a healthy individual, the liver produces a range of serum proteins including
albumin, clotting factors and complement. During acute infection hepatocytes are induced to produce a range of antimicrobial proteins,
inflammatory mediators, coagulation factors and opsonins, collectively known as the acute phase response. Inflammatory cytokines
produced in the liver (for example, IL-6) enhance the acute phase response, alter thermoregulation and induce leukocytosis.
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often considered a feature of pathology but resolving fibrosis is
also essential for liver wound repair and restoration of tissue
homeostasis (Figure 4). Fibrosis only becomes clinically rele-
vant when it alters tissue structure and function due to
dysregulated or excessive inflammation.
In the resolution phase of acute liver fibrosis, macrophages
produce a range of pro-resolution mediators, which increase
expression of matrix metalloproteinases and suppress matrix
metalloproteinase inhibitors.88 At the same time, NK
cell-mediated cytotoxicity against HSCs contributes to the
regulation of intrahepatic fibrosis. Trans-differentiation of acti-
vated HSCs into myofibroblasts alters the balance
of activating and inhibitory cell receptor ligands such
that they are targeted for deletion by NK cells via TRAIL-, FasL-
and NKG2D-dependent mechanisms.89,90 These multifaceted
interactions between immune cell subsets that regulate the repair
process lead many to consider wound healing as a critical
component of the innate immune response to tissue damage.
Table 1 Serum protein synthesis by the liver during the acute phase response
Proteins induced in APR Examples Immune function
Complement proteins C3, C4 and C9 Enhance phagocytosis, act as chemoattractants, induce
cell degranulation, enhance vascular permeability and
induce bacterial cell lysis
Iron-binding proteins Haptoglobin, hemopexin, ferritin and hepcidin Act to reduce free iron in the serum and antimicrobial
functions
Antimicrobial proteins Liver expressed antimicrobial peptide 2, hepcidin Antimicrobial activity
Clotting factors Fibrinogen, prothrombin, factor VIII, factor IX and Von
Willebrand factor
Enhance coagulation
Inflammatory proteins IL-6, lipopolysaccahride-binding protein and secreted
phospholipase A2
Enhance pro-inflammatory signals and potentiate the
APR
Lectins, pentraxins, ficolins
and collectins
C-reactive protein, mannose-binding lectin, collectin liver 1,
ficolin-2 and serum amyloid P
Active complement and enhance phagocytosis
Protease inhibitors α2-Macroglobulin, α1-antichymotrypsin and α1-antitrypsin Anti-inflammatory functions via the inhibition of coagu-
lation, neutrophils and mast cells
Abbreviation: ARP, acute phase response.
Figure 4 Maintenance of local homeostasis in the liver in response to liver damage. Inflammatory processes are vital to maintain liver
homeostasis following cell death or infection. Upon acute injury, cell death or infection, apoptotic hepatocytes release a variety of DAMPs
and/or MAMPs (1) that are recognized by and activate neighboring hepatocytes, HSCs, and liver-resident immune cell populations.
Activated cells secrete inflammatory mediators leading to leukocyte recruitment and HSC trans-differentiation into myofibroblasts, which
initiate fibrosis through the synthesis of extra-cellular matrix components (2). The initiation of inflammation leads to the expression of pro-
resolving factors from recruited leukocytes and myofibroblast apoptosis (3), enabling tissue regeneration and a return to homeostasis (4).
If this resolution phase does not occur persistent inflammation results in the progressive development of liver fibrosis and eventual
cirrhosis. Abbreviations: DAMPs, damage-associated molecular patterns; ECM, extra-cellular matrix components; HSCs, hepatic stellate
cells; MAMPs, microbial associated molecular patterns.
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Inflammation and Liver Regeneration
The capacity of the liver to fully regenerate after injury is
essential for the maintenance of the liver’s important functions
in the control of metabolism and xenobiotic detoxification.
This regenerative capacity is driven by the proliferation of
existing mature hepatocytes in response to environmental
cues.91 The regeneration potential of the liver is driven by
inflammatory mediators (for example, IL-1α, TNFα and IL-6),
growth factors (for example, hepatocyte growth factor and
epidermal growth factor) and liver-resident immune cell
populations.92 The importance of IL-6 is emphasized by the
impaired liver regeneration observed in mice with targeted
disruption of IL-6, which have reduced hepatocyte proliferation
that can be restored with a single pre-operative dose of IL-6.93
Impaired liver regeneration is also observed in mice treated
with antibodies targeting TNFα.94 The pro-regeneration effect
of TNFα requires expression of inducible nitric oxide synthase,
which blocks the potential pro-apoptotic effect of TNFα
signaling, and highlights a small part of the complexity of
inflammatory signals required to regulate liver regeneration.95
KCs play a central role in this liver regeneration via release of
IL-6 and TNFα, which promotes hepatocyte proliferation, and
KC depletion impedes subsequent liver regeneration.96 This KC
activation is driven by neutrophil recruitment to the liver, in
response to inflammatory signals, in an ICAM-1-dependent
manner.96 The complement proteins C3 and C5 also play
important roles in priming KCs and promoting hepatocyte
proliferation following partial hepatectomy.97 In addition to
these pro-regeneration properties, liver-resident immune cell
populations can also inhibit liver regeneration.98 Depletion of
NK cells enhances liver regeneration due to reduced IFNγ
production, which acts to induce hepatocyte cell cycle arrest
and inhibits hepatocyte proliferation.99,100 Depletion of
NKT cells in hepatitis B virus transgenic mice also enhances
liver regeneration due to reduced production of IFNg and
TNFa.101 These liver-resident immune cell populations act as a
negative feedback mechanism, regulating liver regeneration and
returning the liver to homeostasis.
TARGETING IMMUNE DYSREGULATION AS A
THERAPEUTIC STRATEGY IN LIVER DISEASE
Dysregulation of liver inflammation is a hallmark of chronic
infection, autoimmunity and malignancy, which is mediated
by multiple overlapping pathways in different liver diseases.
While homeostatic inflammation and liver fibrosis are aspects
of the healthy adult liver, a lack of resolution or chronic liver
injury lead to progressive liver fibrosis and permanent
liver damage. In these situations, pathological inflammation
promotes the progression of liver fibrosis to cirrhosis and
establishes a dysregulated balance between inflammation and
immunosuppression within the liver. Approaching liver disease
as a range of overlapping pathways leading to the dysregulation
of homeostatic inflammatory processes provides novel avenues
for the development of future therapies targeting inflammation
and resolution within the liver.
Excessive or persistent inflammation characterizes a range of
liver diseases. Persistent activation of innate immune detection
pathways, due to chronic infection, tissue damage, excess
consumption of alcohol or fat, or tumor growth, leads to the
classic features of pathological liver inflammation. Persistent
inflammatory signals, produced by a range of immune cell and
non-hematopoietic cell populations, maintain HSC-derived
hepatic myofibroblasts in an activated state.102 This limits
myofibroblast senescence and reduces the ability of NK cells to
induce myofibroblast apoptosis.98 Within the diseased liver,
excessive inflammation results in the loss of liver tolerogenic
mechanisms, promoting further inflammation. Inflammatory
monocyte-derived macrophages are recruited to the liver where
they promote fibrosis,103 and reduce the ability of KCs
to promote T regulatory cell development.67 This disruption
of hepatic tolerance has important clinical consequences as
liver disease develops. As an example the spread of bacterial
products in advanced cirrhosis/decompensation can lead to a
pro-inflammatory cytokine storm and eventual systemic organ
failure.104 Where treatment options are available clinically, such
as in autoimmune disorders, these rely on the use of general
immunosuppressive drugs.105 In this context, therapeutic
strategies aimed at enhancing the normal tolerogenic liver
mechanisms that lead to the resolution of inflammation,
fibrosis regression and hepatocyte regeneration, may augment
the existing immunosuppressive treatments. The potential of
such strategies can be seen in results from a recent clinical trial,
using a combination of granulocyte colony-stimulating factor
and erythropoietin to enhance liver regeneration, which
improved 12-month survival for patients with advanced
cirrhosis and significantly reduced liver severity scores.106
Normal liver tolerogenic mechanisms can also act to
promote the persistence of liver pathogens, such as hepatitis
C virus, and the growth of primary and metastatic tumors,
which in time establishes a state of dysregulated inflammation.
A number of pathogens specifically target the liver58 and the
liver is also a common site of primary malignancy and
metastasis. The presentation of pathological antigens in the
liver can actively suppress immune responses, thus inducing a
state of immune tolerance to the pathogen or tumour.58,74,75,107
At the same time, innate immune activation, in response to
MAMPs or DAMPs released during infection or tumor growth,
results in persistent inflammation and the upregulation of a
number of immune regulatory pathways aimed at minimizing
excessive tissue damage. This includes expansion of tumor-
promoting immunoregulatory cell populations such as
MDSCs,24,108 epigenetic and metabolic changes resulting in
immune cell tolerance,109 induction of negative regulators of
pro-inflammatory signaling pathways,110 and development of
T-cell exhaustion.107,111 Targeting these immune regulatory
pathways in liver disease could reduce liver pathology (via
promotion of regulatory mechanisms) or induce pathogen/
tumor clearance (via inhibition of regulatory mechanisms).
One such strategy, using immune checkpoint inhibitors to
reverse T-cell exhaustion, is showing promise in the field of
cancer therapy as well as in the context of liver disease. A phase
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II clinical trial of Tremelimumab (which targets cytotoxic
T-lymphocyte-associated protein 4), in patients with hepatitis
C virus infection and hepatocellular carcinoma, resulted in
favorable antitumor activity and antiviral activity, including
transient complete viral response in three patients.112 These
results highlight the potential for therapeutically targeting
immune tolerance in the liver.
EPILOGUE: THE HEALTHY IMMUNOLOGICAL LIVER
Inflammatory mechanisms are crucial to maintaining liver
homeostasis as well as protecting the body from pathogens,
tumors and tissue damage. Hepatic inflammatory mechanisms
initiate, mediate and resolve systemic and local immune
responses and at the same time contribute to liver pathology.
The diverse repertoire of immune cell populations in the liver,
together with the inflammatory potential of non-hematopoietic
hepatic cells, plays a central role in both homeostatic and
pathological inflammation within the liver. The complex inflam-
matory and immunoregulatory interplay within the liver is
required to maintain organ and systemic homeostasis, as well
as mobilize complementary inflammatory mechanisms to protect
against infection, metastasis and tissue damage. We are at last
beginning to dissect out the molecular mechanisms involved in
these apparently contradictory inflammatory processes and to
understand how inflammation is responsible for both normal
liver homeostasis and function and also for liver pathology.
KEY CONCEPTS
1. The healthy adult liver contains large populations of resident
myeloid and lymphoid immune cells.
2. Inflammatory mechanisms in the healthy liver maintain
local organ and systemic homeostasis.
3. Despite a bias toward immune tolerance, hepatic immune
cells can induce robust pro-inflammatory responses upon
tissue damage or infection.
4. The liver plays a central role in the sensing of and the
response to systemic inflammation.
5. Excessive or dysregulated inflammatory activity leads to the
pathology associated with autoimmune, infectious or malig-
nant hepatic disease.
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